. Author manuscript; available in PMC: 2016 Nov 3.

Published in final edited form as: Crit Care Med. 2015 Mar;43(3):603–612. doi: 10.1097/CCM.0000000000000747

Table 1.

PEER-ProTECT participants, compared to ProTECT III study and community consultation participants

	PEER ProTECT Population	ProTECT III Trial Population	Entire ProTECT III Community Consultation Population
Total Participants	85	882	8835
Participant Type
Patient	31 (36%)	882 (100%)	N/A
Surrogate	54 (64%)	0 (0%)	N/A
Gender^*
Female	46 (54%)	232 (26%)	4470 (58%)
Male	39 (46%)	650 (74%)	3280 (42%)
Race^*
White	59 (69%)	659 (75%)	5799 (78%)
Black	11 (13%)	134 (15%)	1007 (14%)
Other	15 (18%)^†	89 (10%)	581 (8%)
Ethnicity^*
Hispanic	6 (7%)	125 (14%)	395 (7%)
Age^*
Mean (SD)	46 (16)	39 (17)	41 (16)
< 30	15 (18%)	N/A	N/A
31–50	31 (36%)	N/A	N/A
51–70	33 (39%)	N/A	N/A
> 70	5 (6%)	N/A	N/A
Not reported	1 (1%)	N/A	N/A
Education^*
≤ High School	41 (48%)	N/A	1289 (18%)
> High School	44 (52%)	N/A	5837 (82%)

PEER ProTECT demographic data is reported for patients and surrogates together

^†

“Other” racial group in PEER ProTECT includes self-identified Latinos/Hispanics as they were subsequently not asked for race after ethnicity question